Structure of Sofosbuvir
CAS No.: 1190307-88-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM.
Synonyms: GS-7977; PSI-7977; Resof
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Kupke, Paul ; Adenugba, Akinbami ; Schemmerer, Mathias ; Bitterer, Florian ; Schlitt, Hans J. ; Geissler, Edward K. , et al.
Abstract: Hepatitis E virus (HEV) is a major cause of acute hepatitis globally. Chronic and fulminant courses are observed especially in immunocompromised transplant recipients since administration of ribavirin (RBV) does not always lead to a sustained virol. response. By in vitro stimulation of NK cells through hepatoma cell lines inoculated with a full-length HEV and treatment with RBV, we analyzed the viral replication and cell response to further elucidate the mechanism of action of RBV on immune cells, especially NK cells, in the context of HEV infection. Co-culture of HEV-infected hepatoma cells with PBMCs and treatment with RBV both resulted in a decrease in viral replication, which in combination showed an additive effect. An anal. of NK cell functions after stimulation revealed evidence of reduced cytotoxicity by decreased TRAIL and CD107a degranulation. Simultaneously, IFN-γ production was significantly increased through the IL-12R pathway. Although there was no direct effect on the IL-12R subunits, downstream events starting with TYK-2 and subsequently pSTAT4 were upregulated. In conclusion, we showed that RBV has an immunomodulatory effect on the IL-12R pathway of NK cells via TYK-2. This subsequently leads to an enhanced IFN-γ response and thus, to an additive antiviral effect in the context of an in vitro HEV infection.
Show More >
Keywords: ribavirin ; hepatitis E virus ; transplantation ; immunosuppression ; NK cells
Show More >
Frauke Assmus ; Jean-Sélim Driouich ; Rana Abdelnabi ; Laura Vangeel ; Franck Touret ; Ayorinde Adehin , et al.
Abstract: In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.
Show More >
Keywords: COVID-19 ; drug repurposing ; translational medicine ; pandemics ; clinical trials
Show More >
Purchased from AmBeed: 55981-09-4 ; 23828-92-4 ; 198904-31-3 ; 59721-29-8 ; 259793-96-9 ; 1190307-88-0 ; 481-49-2 ; 155213-67-5 ; 61718-82-9
Show More >
Prediction of Chameleonic Efficiency
Laurent David ; Mark Wenlock ; Patrick Barton ; Andreas Ritzén ;
Abstract: Chameleonic properties, i.e., the capacity of a molecule to hide polarity in non-polar environments and expose it in water, help achieving sufficient permeabilily and solubility for drug molecules with high MW.We present models ofexperimental measures of polarity for a set of 24 FDA approved drugs (MW 405-1113)and one PROTAC(MW 1034). Conformational ensembles in aqueous and non-polar environments were generated using molecular dynamics, A linearregression model that predicts chromatographic apparent polarity(EPSA) with a mean unsigned error of 10 A2 was derived based on separate terms for donor, acceptor, and tolal molecular SASA. A good correlation (R'0.92) with an experimental measure of hydrogen bond donor potential, Alog Poa, was found for the mean hydrogenbond donor SASA of the confommational ensemblescaled with Abraham's A hydrogen bond acidity. Two quantitative measures of chameleonic behaviour, the chameleonic efficlency indices, are introduced. We envislon that the methods presented herein will be useful to triage designed molecules and prioritize those with the best chance of achieving acceptable permeabilily and solubility.
Show More >
Keywords: chameleonic properties ; polar surface area ; hydrogen bonding ; molecular dynamics
Show More >
| CAS No. : | 1190307-88-0 |
| Formula : | C22H29FN3O9P |
| M.W : | 529.45 |
| SMILES Code : | C[C@@H](C(OC(C)C)=O)N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@H](N(C(N3)=O)C=CC3=O)[C@](C)(F)[C@@H]2O)=O |
| Synonyms : |
GS-7977; PSI-7977; Resof
|
| MDL No. : | MFCD26523124 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H315-H319-H335 |
| Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501 |
| Description |
Sofosbuvir (GS-7977) is an inhibitor of HCV RNA replication, with an EC50 of 92 nM[1].
|
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| HEK293 cells | 5 μM | 24 h | To assess the cytotoxicity of Sofosbuvir, results showed no significant cytotoxicity | PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007072. |
| Huh-7 cells | 10 μM | 48 h | To evaluate the inhibitory effect of Sofosbuvir on HCV replication, results showed significant inhibition of HCV replication | PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007072. |
| Human fetal neuronal stem cells | 2-125 μM | 48 h | Sofosbuvir significantly inhibited ZIKV infection in human fetal neuronal stem cells with an EC50 of ~32 μM | Antiviral Res. 2017 Jan;137:134-140. |
| Jar cells | 1-500 μM | 72 h | Sofosbuvir significantly inhibited ZIKV replication in Jar cells with EC50 values of 1-5 μM and EC90 values of 12-44 μM | Antiviral Res. 2017 Jan;137:134-140. |
| Huh-7 cells | 1-500 μM | 72 h | Sofosbuvir significantly inhibited ZIKV replication in Huh-7 cells with EC50 values of 1-5 μM and EC90 values of 12-44 μM | Antiviral Res. 2017 Jan;137:134-140. |
| monkey kidney Vero cells | 10–20 µM | 3 days | SOF did not suppress DENV1 production. | Int J Mol Sci. 2024 Feb 7;25(4):2022. |
| hamster kidney BHK-21 cells | 5–50 µM | 48 h | SOF did not suppress the replication of the DENV1 RNA replicon. | Int J Mol Sci. 2024 Feb 7;25(4):2022. |
| human hepatic Huh7 cells | 5–50 µM | 48 h | SOF significantly inhibited the replication of the DENV1 RNA replicon in a dose-dependent manner, with approximately 90% inhibition at 50 µM, without cytotoxicity. | Int J Mol Sci. 2024 Feb 7;25(4):2022. |
| Xenopus laevis oocytes | 19.2 mM | Evaluate the interaction of PSI-6206 with hCNT3 | Nat Chem Biol. 2024 Sep;20(9):1144-1153. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| Mice | HCV infection model | Oral | 30 mg/kg | Once daily for 14 days | To evaluate the antiviral efficacy of Sofosbuvir in vivo, results showed significant reduction in viral load | PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007072. |
| Mice | ZIKV infection model | Oral | 33 mg/kg | 7 consecutive days | Oral administration of Sofosbuvir significantly increased survival rates and prevented weight loss in mice | Antiviral Res. 2017 Jan;137:134-140. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT03282474 | Hepatitis E|Hepatitis Chronic ... More >>Viral Less << | PHASE2 | COMPLETED | 2019-02-18 | Hannover Medical School, Clini... More >>c for Gastroenterology, Hepatology, and Endocrinology, Hanover, Lower Saxony, 30625, Germany|Charité, Campus Virchow-Klinikum, Medical Department, Division of Hepatology and Gastroenterology, Berlin, 13353, Germany|University Medical Center Hamburg-Eppendorf, Center for Internal Medicine, I. Medical Clinic and Polyclinic, Hamburg, 20246, Germany Less << |
| NCT02804386 | Hepatitis C, Chronic | PHASE4 | COMPLETED | 2018-01-30 | Ojha, Duhs, Karachi, Sindh, Pa... More >>kistan Less << |
| NCT02783976 | HCV Infection | COMPLETED | 2018-06-20 | Cuernavaca, Mexico|Durango, Me... More >>xico|Guadalajara, 44680, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Monterrey, 64460, Mexico Less << | |
| NCT04664894 | Safety Issues | COMPLETED | 2019-05-30 | Liver Center Faisalabad, Faisa... More >>labad, Punjab, Pakistan Less << | |
| NCT02907996 | Hepatitis C Virus | COMPLETED | 2021-12-09 | Yonsei University Wonju Severa... More >>nce Christian Hospital, Wonju, Gangwon-do, 26426, Korea, Republic of|CHA Bundang Medical Center, Sungnam, Gyeonggi-d, 463-712, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang, 14068, Korea, Republic of|The Catholic University of Korea Bucheon ST. Mary's Hospital, Bucheon-si, 14647, Korea, Republic of|SoonChunHyang University Bucheon Hospital, Bucheon-Si, 420-767, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of|BongSeng Memorial Hospital, Busan, 48775, Korea, Republic of|Dong-A University Hospital, Busan, 49201, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Kosin University Gospel Hospital, Busan, 49267, Korea, Republic of|Inje University Busan Paik Hospital, Busan, 614-735, Korea, Republic of|Busan St. Mary's Hospital, Busan, Korea, Republic of|Busan Veterans Hospital, Busan, Korea, Republic of|Maryknoll Medical Center, Busan, Korea, Republic of|Changwon Fatima Hospital, Changwon, 51394, Korea, Republic of|Dankook University Hospital, Cheonan, 31116, Korea, Republic of|SoonChunHyang University Cheonan Hospital, Cheonan, 31151, Korea, Republic of|Hallym University ChunCheon Sacred Heart Hospital, Chuncheon-si, 24253, Korea, Republic of|Konkuk University Chungju Hospital, Chungju, 27376, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, 41931, Korea, Republic of|Yeungnam University Medical Center, Daegu, 42415, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, 42472, Korea, Republic of|Kyungpook National University Hospital, Daegu, 700-721, Korea, Republic of|Kyungpook national university medical center Chil-Gok, Daegu, 700-721, Korea, Republic of|DaeJeon ST. Mary's Hospital, Daejeon, 301-723, Korea, Republic of|Chungnam National University Hospital, Daejeon, 35015, Korea, Republic of|Daejeon Eulji Medical Center, Daejeon, 35233, Korea, Republic of|GangNeung Asan Hospital, Gangneung, 25440, Korea, Republic of|National Health Insurance Cooperation Ilsan Hospital, Goyang-si, 10444, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang, 10326, Korea, Republic of|Myongji Hospital, Goyang, 10475, Korea, Republic of|Kumi Cha Hospital, Gumi, 39295, Korea, Republic of|Hanyang University Guri Hospital, Guri, 11923, Korea, Republic of|Konkuk University Medical Center, Gwangjin-gu, 05030, Korea, Republic of|Chosun University Hospital, Gwangju, 501-717, Korea, Republic of|Kwangju Christian Hospital, Gwangju, 61661, Korea, Republic of|Dongguk University Gyeongju Hospital, Gyeongju, 38067, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, 58128, Korea, Republic of|WonKwang University Hospital, Iksan, 54538, Korea, Republic of|The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, 21431, Korea, Republic of|Inha University Hospital, Incheon, 22332, Korea, Republic of|Catholic Kwandong University International St. Mary's Hospital, Incheon, 22711, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 405-760, Korea, Republic of|Cheju Halla General Hospital, Jeju-Si, 63127, Korea, Republic of|Chonbuk National University Hospital, Jeonju-si, Korea, Republic of|Presbyterian Medical Center, Jeonju, 54987, Korea, Republic of|Gyeongsang National University Hospital, Jinju, 52727, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, 13620, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, 03181, Korea, Republic of|Seoul National University Hospital, Seoul, 03830, Korea, Republic of|SoonChunHyang University Hospital, Seoul, 04401, Korea, Republic of|Hanyang University Hospital, Seoul, 04763, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, 05535, Korea, Republic of|Chung-Ang University Hospital, Seoul, 06973, Korea, Republic of|Boramae Medical Center, Seoul, 07061, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, 07985, Korea, Republic of|Inje University Seoul Paik Hospital, Seoul, 100-032, Korea, Republic of|Severance Hospital, Seoul, 120-752, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Korea University Guro Hospital, Seoul, 152-703, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Nowon Eulji Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, 41931, Korea, Republic of|Ajou University Hospital, Suwon, 16499, Korea, Republic of|The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, 11765, Korea, Republic of|Ulsan University Hospital, Ulsan, 44033, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, 50612, Korea, Republic of|Yongin Severance Hospital, Yongin, 17046, Korea, Republic of Less << |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.89mL 0.38mL 0.19mL |
9.44mL 1.89mL 0.94mL |
18.89mL 3.78mL 1.89mL |
|
Tags: Sofosbuvir | GS-7977 | PSI-7977 | GS7977 | GS 7977 | PSI7977 | PSI 7977 | PSI-7977 | HCV | Hepatitis C virus | NS5B inhibitor | direct-acting antiviral | hepatitis C virus | RNA polymerase | DAA | 1190307-88-0
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


